IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
Status:
Completed
Trial end date:
2018-12-12
Target enrollment:
Participant gender:
Summary
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial.
Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2
mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be
enrolled.